[go: up one dir, main page]

MX9305528A - Complejos polipeptidos y proteinicos modificados por oxido de polietileno liofilizado, con ciclodextrina. - Google Patents

Complejos polipeptidos y proteinicos modificados por oxido de polietileno liofilizado, con ciclodextrina.

Info

Publication number
MX9305528A
MX9305528A MX9305528A MX9305528A MX9305528A MX 9305528 A MX9305528 A MX 9305528A MX 9305528 A MX9305528 A MX 9305528A MX 9305528 A MX9305528 A MX 9305528A MX 9305528 A MX9305528 A MX 9305528A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
polypeptide
polyethylene oxide
complexes modified
proteinic
Prior art date
Application number
MX9305528A
Other languages
English (en)
Inventor
Christopher P Phillips
Robert A Snow
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of MX9305528A publication Critical patent/MX9305528A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan composiciones proteínicas liofilizadas biológicamente activas, que contienen óxido polialquilénico de bajo diol, tales como glicol polietilénico, ligado covalentemente con una sustancia proteinácea biológicamente activa, y combinado con el crioprotector ciclodextrina.
MX9305528A 1993-02-25 1993-09-09 Complejos polipeptidos y proteinicos modificados por oxido de polietileno liofilizado, con ciclodextrina. MX9305528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/023,182 US5298410A (en) 1993-02-25 1993-02-25 Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Publications (1)

Publication Number Publication Date
MX9305528A true MX9305528A (es) 1994-08-31

Family

ID=21813561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305528A MX9305528A (es) 1993-02-25 1993-09-09 Complejos polipeptidos y proteinicos modificados por oxido de polietileno liofilizado, con ciclodextrina.

Country Status (18)

Country Link
US (4) US5298410A (es)
EP (1) EP0614666A1 (es)
JP (1) JPH06256222A (es)
KR (1) KR940019312A (es)
AU (1) AU660843B2 (es)
CA (1) CA2106519A1 (es)
CZ (1) CZ38194A3 (es)
FI (1) FI940909A7 (es)
HU (1) HUT71586A (es)
IL (1) IL108777A (es)
MX (1) MX9305528A (es)
MY (1) MY131553A (es)
NO (1) NO940663L (es)
NZ (1) NZ248590A (es)
PH (1) PH30462A (es)
RU (1) RU94006023A (es)
SK (1) SK23294A3 (es)
TW (1) TW260611B (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
CA2114163C (en) * 1993-01-29 2002-04-30 Nobuo Nishiki Method for stabilizing antigenicity of myeloperoxidase
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (fr) * 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JPH0776700A (ja) * 1993-07-14 1995-03-20 Senju Pharmaceut Co Ltd コンタクトレンズ用剤の安定化方法
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
AU697440B2 (en) * 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5861148A (en) * 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
JP4067058B2 (ja) * 1995-03-10 2008-03-26 中村 敏一 Ｐｅｇ化ｈｇｆ
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5868868A (en) * 1995-06-19 1999-02-09 Alcon Laboratories, Inc. Peg-modified proteases and methods of use in contact lens cleaning
EP0874893A2 (en) * 1995-12-29 1998-11-04 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
ATE298582T1 (de) 1996-04-19 2005-07-15 Alpha Therapeutic Corp Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
US6072040A (en) * 1996-10-15 2000-06-06 Medical Analysis Systems, Inc. Stabilized conjugates of uncomplexed subunits of multimeric proteins
EP0973384A4 (en) * 1997-02-13 2004-10-13 Sky High Llc ORGAN PRESERVATION SOLUTION
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
GB9815785D0 (en) * 1998-07-20 1998-09-16 Cerebrus Ltd Chemical compounds
PT2316475T (pt) 1998-08-06 2017-12-21 Univ Duke Uricase tetramérica isolada
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
EP2599503B1 (en) 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1282411A4 (en) * 2000-04-26 2008-05-21 Charlotte Mecklenburg Hospital METHOD FOR THE TREATMENT OF CANCER
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
SG98393A1 (en) * 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US7195923B2 (en) * 2001-01-31 2007-03-27 Scripps Laboratories, Inc. Ratiometric determination of glycated protein
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002094324A1 (en) * 2001-05-18 2002-11-28 Institute Of Materials Research & Engineering Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
EP1419191B1 (en) 2001-08-22 2007-10-17 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
EP1463804A1 (en) * 2001-12-21 2004-10-06 Rigshospitalet Improved gamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux
US20050132430A1 (en) * 2001-12-21 2005-06-16 Mogens Baltsen Igamete recruitment and developmental competence in mammals by inhibiting the de-nova sterol biosynthesis and/or promoting sterol efflux
SK3102004A3 (sk) * 2002-01-18 2005-01-03 Biogen Idec MA Inc. Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
IL163667A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
CA2476769A1 (en) * 2002-02-22 2003-09-04 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN100519643C (zh) 2002-07-19 2009-07-29 奥默罗斯公司 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
BR122012021252B8 (pt) 2002-09-06 2021-05-25 Cerulean Pharma Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
ES2380622T5 (es) 2003-05-29 2018-05-30 Shire Llc Compuestos de anfetamina resistentes al abuso
KR101131411B1 (ko) * 2003-07-22 2012-07-05 넥타르 테라퓨틱스 중합체 알코올로부터 관능화된 중합체의 제조 방법
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
NZ583573A (en) * 2003-12-16 2011-12-22 Nektar Therapeutics Pegylated naloxol
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
JP5131955B2 (ja) * 2004-08-05 2013-01-30 旭化成ファーマ株式会社 プロテアーゼ反応促進剤及び／又は色素の安定化剤を含む試薬
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1871874B1 (en) 2005-04-11 2015-04-08 Crealta Pharmaceuticals LLC Variant forms of urate oxidase and use thereof
HU229626B1 (hu) 2005-04-11 2014-03-28 Savient Pharmaceuticals Urát oxidáz változat és alkalmazása
EP1896610A2 (en) * 2005-05-03 2008-03-12 Handylab, Inc. Lyophilized pellets
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
ATE524509T1 (de) 2005-07-18 2011-09-15 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
KR100664969B1 (ko) * 2005-08-26 2007-01-04 아이디비켐(주) 고순도의 메톡시폴리에틸렌글리콜 및 그들의 유도체의제조방법
CN100360666C (zh) * 2005-11-29 2008-01-09 沈阳农业大学 一种修饰玉米sod的方法
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US20070173634A1 (en) * 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
PL2013225T3 (pl) * 2006-04-12 2015-06-30 Crealta Pharmaceuticals Llc Oczyszczanie białek z zastosowaniem kationowego środka powierzchniowo czynnego
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US8222039B2 (en) * 2007-02-22 2012-07-17 Biovectra Inc. Process for purification of water soluble polymers
JP4697809B2 (ja) * 2007-02-22 2011-06-08 旭化成ファーマ株式会社 ロイコ色素の安定化方法
RU2007131782A (ru) * 2007-08-22 2009-02-27 Общество с ограниченной ответственностью "Концерн O3" (RU) Гипогликемическое средство и способ его получения
RU2007137048A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
RU2007137044A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием
PT2203181T (pt) * 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
JP5569787B2 (ja) * 2009-03-31 2014-08-13 日油株式会社 高分子量ポリエチレングリコール化合物の精製方法
JP5713274B2 (ja) 2009-03-31 2015-05-07 日油株式会社 高分子量ポリオキシアルキレン誘導体の精製方法
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
WO2011063421A1 (en) * 2009-11-23 2011-05-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
US8163869B1 (en) 2010-12-27 2012-04-24 Nof Corporation Purification method of carboxyl group-containing polyoxyethylene derivative
US9090769B2 (en) 2011-04-05 2015-07-28 Ticona Llc Molded articles having a swirl-like or marble-like appearance and compositions for producing same
US20120302505A1 (en) * 2011-04-21 2012-11-29 Fetzer Oliver S Cyclodextrin-based polymers for therapeutic delivery
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
CA3095299A1 (en) * 2018-03-29 2019-10-03 Nof Corporation Method for purifying trityl group-containing monodispersed polyethylene glycol
EP4249069B1 (en) * 2018-06-07 2025-11-19 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN109206598A (zh) * 2018-09-10 2019-01-15 武汉轻工大学 聚乙二醇-聚丙交酯嵌段共聚物的制备方法以及药物载体
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
CN116769154A (zh) * 2023-07-06 2023-09-19 四平欧凯科技有限公司 单甲氧基聚乙二醇巯基的制备方法
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
US4970216A (en) * 1986-03-17 1990-11-13 Richardson Vicks, Inc. Skin treatment composition and method
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5183809A (en) * 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5182270A (en) * 1989-08-03 1993-01-26 Iolab Corporation Stabilizing preparation for thymoxamine
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5145644A (en) * 1990-12-20 1992-09-08 Allergan, Inc. Hydrogen peroxide destroying compositions and methods of making and using same
JPH04248984A (ja) * 1991-02-05 1992-09-04 Kuraray Co Ltd スーパーオキシドジスムターゼ誘導体およびその製造方法
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Also Published As

Publication number Publication date
MY131553A (en) 2007-08-30
HUT71586A (en) 1995-12-28
AU660843B2 (en) 1995-07-06
NO940663L (no) 1994-08-26
NZ248590A (en) 1995-07-26
FI940909L (fi) 1994-08-26
CA2106519A1 (en) 1994-08-26
NO940663D0 (no) 1994-02-25
FI940909A0 (fi) 1994-02-25
TW260611B (es) 1995-10-21
RU94006023A (ru) 1996-04-20
US5334382A (en) 1994-08-02
US5298410A (en) 1994-03-29
HU9400561D0 (en) 1994-05-30
US5529915A (en) 1996-06-25
JPH06256222A (ja) 1994-09-13
SK23294A3 (en) 1995-02-08
FI940909A7 (fi) 1994-08-26
US5389381A (en) 1995-02-14
IL108777A0 (en) 1994-06-24
EP0614666A1 (en) 1994-09-14
KR940019312A (ko) 1994-09-14
IL108777A (en) 1998-02-08
CZ38194A3 (en) 1994-10-19
AU4616293A (en) 1994-09-01
PH30462A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
MX9305528A (es) Complejos polipeptidos y proteinicos modificados por oxido de polietileno liofilizado, con ciclodextrina.
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
GT199700044A (es) Complejos de inclusion de sales de aril-heterociclicos
DE69823055D1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
PT689459E (pt) Novo agente para o controlo da actividade celular
DE69232725D1 (de) Synthetische dna-sequenz mit verstärkter isektizider aktivität in mais
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
CA2155185A1 (en) Totally synthetic affinity reagents
AU4660789A (en) Polypeptide derivatives
DE60040274D1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
DE69034091D1 (de) Herstellung von Hämoglobin und Analogen davon in Nicht-Erythrozytzellen
DE69942231D1 (de) Ortspezifische duale pegylation von proteine
PT1346034E (pt) Polipéptido da protease de clivagem do factor de von willebrand (vwf), ácido nucleico que codifica o polipéptido e utilização do polipéptido
ATE199377T1 (de) Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung
EP0515516A4 (en) Totally synthetic affinity reagents
ATE471956T1 (de) Verzweigte polyalkylenglykole
AR029644A1 (es) Proteina aislada, polinucleotido aislado, celula huesped transgenica, metodo para controlar una plaga que no es de mamiferos, cultivo biologicamente puro
FR2662698B1 (es)
EP0422125A4 (en) Platelet blocking peptides
ATE111746T1 (de) Polymyxinkonjugate.
FR2675807B1 (fr) Conjugue de calcitonine et de polyethylene glycol.
ES2066857T3 (es) Composiciones detergentes.
ATE157671T1 (de) Synthetische peptide als lungensurfactants mit kovalent gebundenen antioxidantien
DE69120390D1 (de) Kollagen-bindendes protein sowie dessen herstellung
DE69636714D1 (de) G-CSF TPO Fusionsproteine

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees